Ignite Creation Date:
2025-12-26 @ 2:38 PM
Ignite Modification Date:
2025-12-29 @ 11:41 AM
Study NCT ID:
NCT05597306
Status:
SUSPENDED
Last Update Posted:
2024-12-17
First Post:
2022-10-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Sponsor:
Terrence J Bradley, MD
Organization:
Study Overview
Official Title:
VenBom: a Phase 1 Study of Bomedemstat (IMG-7289), a Novel Inhibitor of Lysine-Specific Demethylase 1 (LSD1), in Combination with Venetoclax in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
SUSPENDED
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study put on hold due to Investigational Product (IP) availability
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VenBom
Brief Summary:
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2022-09456 | REGISTRY | NCI Clinical Trials Reporting Program (NCI CTRP) | View |